Topics:

Juvenile Arthritis

Will You Buy In on the Next Biosimilar?

The FDA has deferred a scheduled meeting about Remsima, the infliximab biosimilar already approved in Europe and still awaiting judgment in the US. But approval of the first US biosimilar (a version of the cancer drug filgrastim) prompted warnings from two organizations concerned with rheumatic disease, including the ACR. Are you ready the next challenge to your clinical judgment?

Juvenile Arthritis

Young adults with rheumatic disease may claim they want to be independent. But a survey shows that above all (except, of course, you) they rely on their mothers for help and guidance.

juvenile arthritis

The TNF-α blocker improved growth rates for many preadolescent girls with juvenile arthritis, especially those who hadn't been taking steroids.

Positioning of the probe is "three-quarters of the battle" in diagnosing synovitis of the wrist or hand, says Dr. DeMarco in this video. But gel technique and pressure are crucial to gaining accurate clinical information from ultrasound imaging of this condition.

(ACR2014) Our rheumatologist correspondent found three issues of particular interest: a biomarker test that has gone quickly to market, new diagnostic criteria for gout, and the potential of ultrasound for Sjögren syndrome.

The background risk of cancer in JIA is at least double that in the general population. But a new review finds that such cases are rare, and not linked solely to biologics used to treat the condition.

Macrophage activation syndrome, a devastating complication of some rheumatic conditions, shows pathologic similarities to a rare hereditary condition. Genetic studies imply that their similarities may be more than coincidental.

Pages

Subscribe to Juvenile Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.